Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
19.09
+1.24 (+6.95%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
Next >
Unveiling 3 Analyst Insights On Arcturus Therapeutics
October 01, 2024
Via
Benzinga
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
September 30, 2024
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...
Via
Benzinga
Exposures
COVID-19
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
June 25, 2024
Via
Benzinga
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
June 12, 2024
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).
Via
Benzinga
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
March 11, 2024
Via
Benzinga
Recap: Arcturus Therapeutics Q4 Earnings
March 07, 2024
Via
Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
June 10, 2024
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...
Via
Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
June 07, 2024
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 07, 2024
Via
Benzinga
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
May 28, 2024
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.
Via
Benzinga
Earnings Preview: Arcturus Therapeutics
March 06, 2024
Via
Benzinga
Evaluating NASDAQ:ARCT for Growth Investment Opportunities.
February 27, 2024
High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this.
Via
Chartmill
Is NASDAQ:ARCT suited for growth investing?
February 06, 2024
Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing?
Via
Chartmill
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
May 28, 2024
Via
Benzinga
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
May 09, 2024
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
Via
Benzinga
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
March 07, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Via
InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
Via
InvestorPlace
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
February 20, 2024
We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today.
Via
InvestorPlace
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 23, 2024
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
January 16, 2024
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations
December 26, 2023
Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
Via
Chartmill
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
December 13, 2023
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Via
InvestorPlace
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
December 13, 2023
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 04, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.